In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig.
The long QT syndrome is characterized by a prolongation of the QT interval measured on the surface electrocardiogram. Prolonging the QT interval increases the risk of dangerous ventricular fibrillations, eventually leading to sudden cardiac death. Pharmacologically induced QT interval prolongations are most often caused by antagonizing effects on the repolarizing cardiac current called IKr. In humans IKr is mediated by the human ether-a-go-go related gene (hERG) potassium channel. We recently presented NS3623, a compound that selectively activates this channel. The present study was dedicated to examining the in vivo effects of NS3623. Injection of 30 mg/kg NS3623 shortened the corrected QT interval by 25 +/- 4% in anaesthetized guinea pigs. Accordingly, 50 mg/kg of NS3623 shortened the QT interval by 30 +/- 6% in conscious guinea pigs. Finally, pharmacologically induced QT prolongation by a hERG channel antagonist (0.15 mg/kg E-4031) could be reverted by injection of NS3623 (50 mg/kg) in conscious guinea pigs. In conclusion, the present in vivo study demonstrates that injection of the hERG channel agonist NS3623 results in shortening of the QTc interval as well as reversal of a pharmacologically induced QT prolongation in both anaesthetized and conscious guinea pigs.
Hansen
Rie Schultz
RS
NeuroSearch A/S, Ballerup, Denmark.
Olesen
Søren-Peter
SP
Rønn
Lars Christian B
LC
Grunnet
Morten
M
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D003243:Consciousness; D051668:Delayed Rectifier Potassium Channels / Q000819:agonists* / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D051638:Ether-A-Go-Go Potassium Channels / Q000819:agonists* / Q000037:antagonists & inhibitors; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced / Q000503:physiopathology; D010671:Phenylurea Compounds / Q000494:pharmacology*; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D051668:Delayed Rectifier Potassium Channels; D051638:Ether-A-Go-Go Potassium Channels; C423868:NS 3623; D010671:Phenylurea Compounds; D010880:Piperidines; D011725:Pyridines; D013777:Tetrazoles; C063968:E 4031